News | Radiopharmaceuticals and Tracers | October 27, 2017

Michael J. Fox Foundation and Tau Consortium Developing PET Tracers for Neurodegenerative Disease

Partnership will focus on creating imaging tracers for the detection of alpha-synuclein and tau proteins in the living brain

Michael J. Fox Foundation and Tau Consortium Developing PET Tracers for Neurodegenerative Disease

October 27, 2017 — The Michael J. Fox Foundation for Parkinson's Research (MJFF) and the Tau Consortium announced a funding partnership to accelerate development of novel positron emission tomography (PET) imaging tracers for the detection of the alpha-synuclein and tau proteins in the living brain.

Several neurodegenerative diseases — Parkinson's disease, Lewy body dementia, multiple system atrophy, progressive supranuclear palsy and frontotemporal dementia, among others — involve the aggregation of alpha-synuclein and/or tau. Tools to detect the location and abundance of these proteins would improve clinical care and speed drug development by allowing earlier and more definitive diagnosis, more precise trial subject selection, and more efficient and conclusive therapeutic impact assessment.

"The ability to monitor disease, potentially even before symptom onset, would revolutionize the patient care experience and the pace of drug development," said MJFF CEO Todd Sherer, Ph.D. "This partnership with the Tau Consortium will bring us closer to that goal."

Patrick Brannelly, program director of the Tau Consortium, said, "The process of developing a new PET tracer is challenging, complex and iterative. It makes sense for nonprofits and industry to pool their resources in pursuit of success."

Under this new partnership, the Tau Consortium and MJFF will convene and co-fund a team of leading scientists who will closely coordinate their development of compounds that may bind to alpha-synuclein or tau. Gil Rabinovici, M.D., of the University of California, San Francisco, will direct the initiative. The inaugural grantees are Chester Mathis, Ph.D., director of the University of Pittsburgh PET Facility, and Neil Vasdev, Ph.D., co-founder of MedChem Imaging LLC.

"It's an honor to work alongside these outstanding investigators and as the director of such an important initiative," said Rabinovici. "Presently, these protein aggregates can be measured only at autopsy. Our field needs better tools to enable earlier intervention with potentially disease-modifying treatments."

PET tracers to evaluate protein load in the living brain would allow clinicians and researchers to diagnose people in prodromal or early disease stage, leading care decisions and earlier intervention with potentially disease-modifying treatments. A hypothesis for why some drugs in testing fail is that study participants are too advanced in the disease; a nuclear imaging tracer would allow testing in earlier-stage volunteers. Additionally, data from PET tracers would allow researchers to evaluate the biological impact of their candidate drugs.

Given the importance of this technology, MJFF and the Tau Consortium have invested significantly in this area of research. For example, The Michael J. Fox Foundation is supporting other projects pursuing an alpha-synuclein PET tracer and last year announced a $2 million prize to the first group to develop a viable selective tracer and agree to make the tool available broadly.

For more information:,

Related Content

FDA Clears CereMetrix’s Neuroimaging Analytics and Clinical Workflow Platform
Technology | Neuro Imaging | March 15, 2018
March 15, 2018 – CereMetrix, a subsidiary of CereHealth Corp., ha
Imaging agent helps predict success of lung cancer therapy
News | Oncology Diagnostics | March 08, 2018
March 8, 2018 – Doctors contemplating the best therapy for...
The yellow in the anterolateral entorhinal cortex of the young brain indicates significant activity, something that is absent in the older brain.

This figure shows two different brains that are aligned to a common template space for comparison. The yellow in the anterolateral entorhinal cortex of the young brain indicates significant activity, something that is absent in the older brain. CREDIT: Zachariah Reagh

News | Nuclear Imaging | March 08, 2018
As we get older, it's not uncommon to experience "senior moments," in which we forget where we parked our car or call...
Axumin PET Agent Added to NCCN Guidelines for Suspected Recurrent Prostate Cancer
News | PET Imaging | February 21, 2018
Blue Earth Diagnostics announced that Axumin (fluciclovine F 18) injection has been added to the National Comprehensive...
Radiography Education Enrollment Shows Marginal Rise in 2017
News | Business | February 15, 2018
Directors of radiography educational programs report the number of enrolled students increased slightly in 2017, while...
A Tc99m SPECT cardiac exam showing myocardial perfusion in the heart.

Technetium-99m is primarily used for the detection of cancer and to assess perfusion defects in the heart caused by heart attacks or other conditions.

Feature | Radiopharmaceuticals and Tracers | February 08, 2018 | Dave Fornell
February 8, 2018 — The U.S.
PSMA PET-CT Clearly Differentiates Prostate Cancer from Benign Tissue

68Ga-PSMA PET/CT images showing multifocal PCA in peripheral zone with GS of 5 1 5 5 10. (A and C) Axial PET images. (B and D) Fused PET/CT images. SUVmax of lesion in B was 84.3 and that of lesion in D was 5.7. IRS was 3, and 80% of cells were stained. Credit: Senior author V Prasad, Charité Universitätsmedizin Berlin, Berlin, Germany.

News | PET-CT | February 05, 2018
February 5, 2018 — Using nuclear medicine...
MedyMatch Receives FDA Device Designation for Intracranial Hemorrhage Software
News | Computed Tomography (CT) | February 01, 2018
February 1, 2018 – MedyMatch Technology, a company focused on helping physicians provide accurate patient assessment
Machine Learning Techniques Generate Clinical Labels of Medical Scans
News | Artificial Intelligence | January 31, 2018
Researchers used machine learning techniques, including natural language processing algorithms, to identify clinical...
Brain-scan guided emergency stroke treatment can save more lives
News | Neuro Imaging | January 25, 2018
January 25, 2018 – Advances in brain imagin...
Overlay Init